Evommune (EVMN) vs Century Therapeutics (IPSC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Century Therapeutics is the larger company by market cap ($231.8 million vs $225.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVMN | IPSC |
|---|---|---|
| Share price | $6.22 | $1.28 |
| Market cap | $225.74M | $231.78M |
| 1-day change | -5.90% | -3.03% |
| YTD return | -63.67% | +28.64% |
| 1-year return | — | +128.98% |
| 5-year return | — | -93.37% |
| EPS (TTM) | $-3.75 | $-0.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.20 | $3.04 |
| 52-week low | $6.08 | $0.435 |
| Distance from 52-week high | -81.27% | -57.89% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +287.94% | +271.09% |
| Average volume | 675.52K | 658.60K |
| Shares outstanding | 36.29M | 181.08M |
| Employees | 48 | 78 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Evommune
EVMN stock →Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Century Therapeutics
IPSC stock →Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 78 employees
EVMN vs IPSC FAQ
Which is bigger, Evommune or Century Therapeutics?
Century Therapeutics (IPSC) is larger, with a market capitalization of $231.78M compared with $225.74M for Evommune (EVMN).
Are Evommune and Century Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Evommune and Biotechnology: Biological Products (No Diagnostic Substances) for Century Therapeutics.